AI identifies tumor aging patterns to predict immunotherapy response across multiple cancer types
Even when given the same drug, some patients respond well while others show little or no response. This is particularly true of immunotherapy. A research team at POSTECH (Pohang University of Science and Technology) has developed an artificial intelligence (AI) technology that can predict, in advance, which patients are likely to benefit from treatment.
A research team at POSTECH has developed an artificial intelligence (AI) technology that can predict in advance which patients are likely to benefit from immunotherapy, based on genetic information from cancer patients. Immunotherapy, which works by helping the patient's own immune system fight the cancer, has the advantage of producing long-lasting responses.
However, a significant number of patients do not respond to immunotherapy, leading to substantial costs and lost time. The challenge lies in the fact that the environment surrounding a tumor varies considerably from patient to patient, with senescent cells in the tumor microenvironment suppressing immune-cell activity. The research team took a step-by-step approach, first identifying tumors with a senescent microenvironment and then progressively stratifying patients to determine their likelihood of responding to treatment.
This method outperformed current biomarkers and achieved robust predictive performance across diverse patient populations.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
